Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights

Periklis G. Foukas; Sotirios Tsiodras; Panagiota Economopoulou; Aris Spathis; Maria Mademli; Konstantinos Leventakos; Amanda Psyrri; Petros Karakitsos; Ioannis G. Panayiotides

doi:10.1016/j.idcr.2018.01.013

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights

Periklis G. Foukas, Sotirios Tsiodras, Panagiota Economopoulou, Aris Spathis, Maria Mademli, Konstantinos Leventakos, Amanda Psyrri, Petros Karakitsos, Ioannis G. Panayiotides

Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.

Original language	English (US)
Pages (from-to)	101-103
Number of pages	3
Journal	IDCases
Volume	11
DOIs	https://doi.org/10.1016/j.idcr.2018.01.013
State	Published - 2018

Keywords

Human Herpesvirus 6
Immunotherapy
Lung cancer
Nivolumab

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1016/j.idcr.2018.01.013

Cite this

@article{7ea0e4ec2fc44706b0b047118dcd32b5,

title = "Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights",

abstract = "The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.",

keywords = "Human Herpesvirus 6, Immunotherapy, Lung cancer, Nivolumab",

author = "Foukas, {Periklis G.} and Sotirios Tsiodras and Panagiota Economopoulou and Aris Spathis and Maria Mademli and Konstantinos Leventakos and Amanda Psyrri and Petros Karakitsos and Panayiotides, {Ioannis G.}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

doi = "10.1016/j.idcr.2018.01.013",

language = "English (US)",

volume = "11",

pages = "101--103",

journal = "IDCases",

issn = "2214-2509",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis

T2 - Potential pathogenetic insights

AU - Foukas, Periklis G.

AU - Tsiodras, Sotirios

AU - Economopoulou, Panagiota

AU - Spathis, Aris

AU - Mademli, Maria

AU - Leventakos, Konstantinos

AU - Psyrri, Amanda

AU - Karakitsos, Petros

AU - Panayiotides, Ioannis G.

PY - 2018

Y1 - 2018

N2 - The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.

AB - The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.

KW - Human Herpesvirus 6

KW - Immunotherapy

KW - Lung cancer

KW - Nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85042229111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042229111&partnerID=8YFLogxK

U2 - 10.1016/j.idcr.2018.01.013

DO - 10.1016/j.idcr.2018.01.013

M3 - Article

AN - SCOPUS:85042229111

SN - 2214-2509

VL - 11

SP - 101

EP - 103

JO - IDCases

JF - IDCases

ER -

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this